Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

CD3; folate receptor

In vitro and mouse studies suggest an anti-CD3 antibody conjugated to folic acid could help treat cancer. The antibody conjugate specifically bound folate receptor-expressing tumor cells and was cytotoxic when cultured with peripheral blood mononuclear cells (PBMCs). In mice with folate receptor-positive nasopharyngeal cancer xenografts, the conjugate plus human PBMCs decreased tumor volume compared with saline plus PBMCs. Next steps include safety studies. This work was performed in collaboration with Ambrx Inc., and the development status of the antibody was not disclosed.

SciBX 6(42); doi:10.1038/scibx.2013.1183
Published online Oct. 31, 2013

Patent and licensing status unavailable

Kularatne, S.A. et al. Angew. Chem. Int. Ed.; published online
Sept. 25, 2013;
doi:10.1002/anie.201306866
Contact: Peter G. Schultz,
The Scripps Research Institute,
La Jolla, Calif.
e-mail:
schultz@scripps.edu